IDEXX Laboratories, Inc. (NASDAQ:IDXX) will be announcing its earnings results on Tuesday, October 31st. Analysts expect the company to announce earnings of $0.74 per share for the quarter. IDEXX Laboratories has set its FY17 guidance at $3.12-3.22 EPS.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 1st. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.85 by $0.10. The company had revenue of $508.90 million during the quarter, compared to analysts’ expectations of $502.44 million. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The firm’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.74 EPS. On average, analysts expect IDEXX Laboratories to post $3.17 EPS for the current fiscal year and $3.56 EPS for the next fiscal year.

IDEXX Laboratories, Inc. (NASDAQ IDXX) traded down 0.47% during mid-day trading on Tuesday, reaching $163.66. The company’s stock had a trading volume of 168,626 shares. The firm has a 50-day moving average of $158.46 and a 200 day moving average of $160.33. IDEXX Laboratories, Inc. has a 1-year low of $102.45 and a 1-year high of $173.01. The firm has a market capitalization of $14.28 billion, a price-to-earnings ratio of 56.30 and a beta of 0.48.

In other news, CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $154.91, for a total transaction of $2,788,380.00. Following the transaction, the chief executive officer now owns 1,043,034 shares of the company’s stock, valued at approximately $161,576,396.94. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Chairman Jonathan W. Ayers sold 13,000 shares of the stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $150.79, for a total value of $1,960,270.00. Following the transaction, the chairman now directly owns 1,044,034 shares in the company, valued at approximately $157,429,886.86. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 151,734 shares of company stock worth $23,436,626. Insiders own 2.77% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/24/idexx-laboratories-inc-idxx-scheduled-to-post-quarterly-earnings-on-tuesday.html.

Several equities research analysts recently issued reports on IDXX shares. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 5th. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research note on Friday, July 14th. CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price objective for the company in a research note on Friday, July 28th. Canaccord Genuity reissued a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, August 22nd. Finally, Bank of America Corporation raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective for the company in a research note on Wednesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $174.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Earnings History for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.